DEFB128: A Potential Drug Target and Biomarker for Various Diseases

Target Name: DEFB128

NCBI ID: G245939

DEFB128

DEFB128: A Potential Drug Target and Biomarker for Various Diseases

Defensin beta-128 (DEFB128) is a protein that is expressed in various cell types of the human body, including epithelial, hematopoietic, and neural cells. It is a member of the Defensin family, which is characterized by the presence of a conserved basic amino acid sequence responsible for their antimicrobial activity. In this article, we will discuss DEFB128 as a drug target and its potential as a biomarker for various diseases.

DEFB128 Structure and Function

The DEFB128 protein is a 160 amino acid long protein that is expressed in various cell types of the human body. It has a molecular weight of 19.9 kDa and a calculated pI of 6.3. DEFB128 is localized to the cytoplasm of the cell and is predominantly monomeric.

The DEFB128 protein has several conserved features that are characteristic of the Defensin family. It contains a conserved basic amino acid sequence that is responsible for its antimicrobial activity. This sequence consists of a catalytic active site, a conserved glycine residue, and a conserved Asp residue . The catalytic active site is located at the N-terminus of the protein and is responsible for the formation of a covalent complex with various molecules, including bacteria and viruses.

In addition to its conserved features, DEFB128 also has a unique mechanism of action that is distinct from other Defensin proteins. It is a potent inhibitor of the host cell's response to bacterial invasion, and it has been shown to protect against bacterial-induced tissue damage in various experimental models.

DEFB128 Potential as a Drug Target

The potential of DEFB128 as a drug target is due to its unique mechanism of action and its ability to inhibit the host cell's response to bacterial invasion. Several studies have shown that DEFB128 can inhibit the recruitment of immune cells to the site of bacterial invasion, including the recruitment of neutrophils. This is important because neutrophils are key mediators of tissue damage and inflammation following bacterial infection.

In addition to its potential as a drug target, DEFB128 has also been shown to be a potential biomarker for various diseases. The Defensin family of proteins has been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The unique mechanism of action of DEFB128 makes it a promising biomarker for these diseases.

DEFB128 Potential as a Biomarker

The Defensin family of proteins has been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The unique mechanism of action of DEFB128 makes it a promising biomarker for these diseases.

One of the main advantages of DEFB128 as a biomarker is its ability to be easily measured and detected in various cell types and tissues. This makes it a potential marker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a biomarker, DEFB128 has also been shown to be involved in the development and progression of various diseases. For example, studies have shown that DEFB128 is involved in the development of cancer by promoting the growth and survival of cancer cells.

Conclusion

In conclusion, DEFB128 is a protein that is expressed in various cell types of the human body and has several unique features that make it a promising drug target and biomarker for various diseases. Its mechanism of action as an inhibitor of bacterial invasion and its potential as a biomarker for a variety of diseases make it an attractive target for further research. Further studies are needed to fully understand the potential of DEFB128 as a drug

Protein Name: Defensin Beta 128

Functions: Has antibacterial activity

The "DEFB128 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB128 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets